Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chemoprevention Clear all
Terminated Phase 2 Interventional Results available

Enzalutamide for Bladder Cancer Chemoprevention

NCT02605863
View directory record Official record
Conditions
Bladder Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Bisphosphonates for Breast Cancer

NCT02781805
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Alendronate
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer

NCT00007631
View directory record Official record
Conditions
Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms
Interventions
Tretinoin 0.1% cream or placebo, Placebo
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer

NCT00570232
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

NCT00033371
View directory record Official record
Conditions
Colorectal Cancer, Familial Adenomatous Polyposis
Interventions
Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

NCT01192204
View directory record Official record
Conditions
Squamous Cell Carcinoma of Mouth, Intraepithelial Neoplasia
Interventions
10% FBR containing bioadhesive gel, placebo gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Louisville, Kentucky • Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

NCT00084409
View directory record Official record
Conditions
Lung Cancer, Precancerous Condition
Interventions
iloprost, placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
6
States / cities
Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed

NCT00002650
View directory record Official record
Conditions
Colorectal Cancer
Interventions
folic acid
Dietary Supplement
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
21 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2009
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Completed No phase listed Observational

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

NCT01399359
View directory record Official record
Conditions
Breast Cancer
Interventions
Counseling session, Questionnaire 1, Questionnaire 2, online questionnaire
Behavioral · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
35 Years to 120 Years · Female only
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

NCT00073073
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Calcium carbonate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Georgetown University
Other
Eligibility
Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional

Chemoprevention of Colorectal Adenomas

NCT00486512
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy
Drug · Procedure
Lead sponsor
Colotech A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Enrolling by invitation Not applicable Interventional

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

NCT06578637
View directory record Official record
Conditions
FAP, Familial Adenomatous Polyposis
Interventions
R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A), R-1,3-Butanediol (30G-B)
Dietary Supplement
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

NCT00002527
View directory record Official record
Conditions
Colorectal Cancer
Interventions
aspirin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
30 Years to 74 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2006
U.S. locations
41
States / cities
Scottsdale, Arizona • San Francisco, California • Miami Beach, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

NCT00006214
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
22
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 3, 2026, 6:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

NCT04496739
View directory record Official record
Conditions
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
Interventions
Cancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
412 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
96
States / cities
Antioch, California • Costa Mesa, California • Duarte, California + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism

NCT02999399
View directory record Official record
Conditions
Smoking
Interventions
Brussel Sprouts, Deuterated Phenanthrene
Other · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Basal Cell Carcinoma Chemoprevention Trial

NCT05212246
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
5% Imiquimod cream, Placebo Vehicle Control Cream
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

NCT01116336
View directory record Official record
Conditions
Cancer of Head and Neck, Neoplasms, Head and Neck
Interventions
Erlotinib, Green Tea Polyphenon E
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 3, 2026, 6:19 PM EDT
Not listed Phase 1 Interventional

Erlotinib in Treating Patients With Barrett Esophagus

NCT00566800
View directory record Official record
Conditions
Esophageal Cancer, Precancerous Condition
Interventions
erlotinib hydrochloride, laboratory biomarker analysis, biopsy
Drug · Other · Procedure
Lead sponsor
Kansas City Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

NCT00001693
View directory record Official record
Conditions
Colorectal Neoplasm, Hereditary Nonpolyposis
Interventions
Celecoxib (SC-58635)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

NCT00256217
View directory record Official record
Conditions
DCIS
Interventions
Anastrozole
Drug
Lead sponsor
Rita Sanghvi, Mehta
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Not applicable Interventional

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

NCT00200174
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene followed by combination therapy, Exemestane followed by combination therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sustainable Healthcenter Implementation PrEP Pilot Study

NCT02074891
View directory record Official record
Conditions
HIV Chemoprophylaxis, HIV Preexposure Prophylaxis
Interventions
coformulated TDF/FTC
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 3, 2026, 6:19 PM EDT